Pioglitazone Helps Protect Against Parkinson's Disease in Monkeys
Author Information
Author(s): Christine R. Swanson, Valerie Joers, Viktoriya Bondarenko, Kevin Brunner, Heather A. Simmons, Toni E. Ziegler, Joseph W. Kemnitz, Jeffrey A. Johnson, Marina E. Emborg
Primary Institution: Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI USA
Hypothesis
The PPAR-γ agonist pioglitazone would modulate the inflammatory reaction induced by the neurotoxin MPTP and prevent nigral cell loss and associated PD syndrome.
Conclusion
Oral administration of pioglitazone is neuroprotective when given early after inducing a parkinsonian syndrome in rhesus monkeys.
Supporting Evidence
- Monkeys treated with 5 mg/kg of pioglitazone showed significant improvements in clinical rating scores compared to placebo.
- Behavioral recovery was linked to preservation of dopaminergic markers in the brain.
- Pioglitazone reduced inflammation in the brain as indicated by decreased CD68 positive microglia.
Takeaway
Giving pioglitazone to monkeys with Parkinson's-like symptoms helped them feel better and protected their brain cells.
Methodology
Rhesus monkeys were injected with a neurotoxin and then treated with different doses of pioglitazone for three months, followed by necropsy and analysis of brain tissue.
Potential Biases
Potential bias in treatment effects due to the small number of animals in each treatment group.
Limitations
The study was limited by the timing of pioglitazone administration and the small sample size.
Participant Demographics
Adult rhesus monkeys (Macaca mulatta), aged 5-7 years.
Statistical Information
P-Value
P = 0.02
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website